Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study.

ABSTRACT:

Background

Benralizumab is a humanized, fucosylated, monoclonal antibody that targets the interleukin 5 (IL-5) α receptor. Several phase III trials have shown that benralizumab can significantly reduce the incidence of acute exacerbations and improve lung function in patients with severe asthma. However, there is a paucity of data from clinical practice. In this prospective study, we evaluated the effectiveness and safety of benralizumab for severe asthma in clinical practice.

Methods

This was a prospective, open-label, single-arm, single-center study in patients with severe asthma in clinical practice (UMIN000031951). Haematological, clinical, functional, and pharmacotherapeutic parameters were evaluated at baseline and at weeks 4 and 12 after initiation of benralizumab.

SUBMITTER: Izumo T 

PROVIDER: S-EPMC7210162 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature